Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NTLA |
---|---|---|
09:32 ET | 24448 | 18.01 |
09:34 ET | 5601 | 17.9527 |
09:36 ET | 16767 | 18.034 |
09:38 ET | 2850 | 18.098 |
09:39 ET | 28475 | 17.99 |
09:41 ET | 18030 | 18.12 |
09:43 ET | 3249 | 18.065 |
09:45 ET | 12473 | 18.06 |
09:48 ET | 9677 | 18.05 |
09:50 ET | 9786 | 17.95 |
09:52 ET | 10613 | 17.93 |
09:54 ET | 7353 | 17.86 |
09:56 ET | 35387 | 17.76 |
09:57 ET | 6193 | 17.76 |
09:59 ET | 34191 | 17.7699 |
10:01 ET | 20781 | 17.65 |
10:03 ET | 9552 | 17.66 |
10:06 ET | 9263 | 17.59 |
10:08 ET | 7775 | 17.6063 |
10:10 ET | 9139 | 17.4743 |
10:12 ET | 10116 | 17.44 |
10:14 ET | 1761 | 17.53 |
10:15 ET | 5928 | 17.61 |
10:17 ET | 14786 | 17.6825 |
10:19 ET | 9089 | 17.73 |
10:21 ET | 6602 | 17.69 |
10:24 ET | 1769 | 17.625 |
10:26 ET | 4716 | 17.59 |
10:28 ET | 1493 | 17.55 |
10:30 ET | 3315 | 17.51 |
10:32 ET | 2441 | 17.545 |
10:33 ET | 8648 | 17.54 |
10:35 ET | 6751 | 17.6 |
10:37 ET | 3750 | 17.6 |
10:39 ET | 575 | 17.62 |
10:42 ET | 2810 | 17.633194 |
10:44 ET | 2900 | 17.61 |
10:46 ET | 2876 | 17.65 |
10:48 ET | 3832 | 17.65 |
10:50 ET | 6720 | 17.61 |
10:51 ET | 8298 | 17.68 |
10:53 ET | 4330 | 17.7 |
10:55 ET | 4253 | 17.6823 |
10:57 ET | 3965 | 17.72 |
11:00 ET | 8010 | 17.73 |
11:02 ET | 18968 | 17.77 |
11:04 ET | 5766 | 17.78 |
11:06 ET | 7279 | 17.79 |
11:08 ET | 14273 | 17.78 |
11:09 ET | 6253 | 17.78 |
11:11 ET | 10570 | 17.78 |
11:13 ET | 3969 | 17.73 |
11:15 ET | 6107 | 17.69 |
11:18 ET | 6908 | 17.72 |
11:20 ET | 2456 | 17.72 |
11:22 ET | 1825 | 17.66 |
11:24 ET | 4213 | 17.63 |
11:26 ET | 7162 | 17.68 |
11:27 ET | 3710 | 17.68 |
11:29 ET | 2779 | 17.64 |
11:31 ET | 2200 | 17.64 |
11:33 ET | 1843 | 17.64 |
11:36 ET | 5810 | 17.645 |
11:38 ET | 5500 | 17.63 |
11:40 ET | 1345 | 17.62 |
11:42 ET | 2709 | 17.62 |
11:44 ET | 1215 | 17.65 |
11:45 ET | 800 | 17.61 |
11:47 ET | 3908 | 17.61 |
11:49 ET | 2118 | 17.59 |
11:51 ET | 2067 | 17.59 |
11:54 ET | 1668 | 17.58 |
11:56 ET | 1881 | 17.64 |
11:58 ET | 1698 | 17.66 |
12:00 ET | 970 | 17.66 |
12:02 ET | 1366 | 17.67 |
12:03 ET | 15229 | 17.73 |
12:05 ET | 3369 | 17.73 |
12:07 ET | 5690 | 17.745 |
12:09 ET | 2708 | 17.74 |
12:12 ET | 3600 | 17.74 |
12:14 ET | 2391 | 17.755 |
12:16 ET | 4401 | 17.74 |
12:18 ET | 5448 | 17.7584 |
12:20 ET | 3977 | 17.75 |
12:21 ET | 4421 | 17.775 |
12:23 ET | 6199 | 17.745 |
12:25 ET | 6317 | 17.7 |
12:27 ET | 3861 | 17.69 |
12:30 ET | 2795 | 17.73 |
12:32 ET | 4016 | 17.71 |
12:34 ET | 450 | 17.72 |
12:36 ET | 2244 | 17.7223 |
12:38 ET | 6340 | 17.72 |
12:39 ET | 1001 | 17.75 |
12:41 ET | 5736 | 17.75 |
12:43 ET | 400 | 17.75 |
12:45 ET | 5108 | 17.79 |
12:48 ET | 1515 | 17.83 |
12:50 ET | 511 | 17.83 |
12:52 ET | 900 | 17.85 |
12:54 ET | 3359 | 17.825 |
12:56 ET | 748 | 17.825 |
12:57 ET | 3168 | 17.81 |
12:59 ET | 2472 | 17.79 |
01:01 ET | 3364 | 17.755 |
01:03 ET | 1466 | 17.77 |
01:06 ET | 2480 | 17.81 |
01:08 ET | 1070 | 17.815 |
01:10 ET | 5512 | 17.81 |
01:12 ET | 3397 | 17.84 |
01:14 ET | 2298 | 17.88 |
01:15 ET | 2722 | 17.88 |
01:17 ET | 1195 | 17.88 |
01:19 ET | 4676 | 17.91 |
01:21 ET | 822 | 17.8949 |
01:24 ET | 4604 | 17.89 |
01:26 ET | 2050 | 17.885 |
01:28 ET | 2359 | 17.845 |
01:30 ET | 500 | 17.83 |
01:32 ET | 1172 | 17.78 |
01:33 ET | 5264 | 17.81 |
01:35 ET | 800 | 17.79 |
01:37 ET | 1200 | 17.78 |
01:39 ET | 6251 | 17.75 |
01:42 ET | 868 | 17.79 |
01:44 ET | 1550 | 17.81 |
01:46 ET | 400 | 17.82 |
01:48 ET | 1154 | 17.815 |
01:50 ET | 925 | 17.79 |
01:51 ET | 3080 | 17.74 |
01:53 ET | 2000 | 17.71 |
01:55 ET | 868 | 17.7089 |
01:57 ET | 4643 | 17.705 |
02:00 ET | 6377 | 17.7 |
02:02 ET | 3161 | 17.68 |
02:04 ET | 640 | 17.69 |
02:06 ET | 4200 | 17.6702 |
02:08 ET | 3727 | 17.67 |
02:09 ET | 3503 | 17.7 |
02:11 ET | 501 | 17.7 |
02:13 ET | 765 | 17.7 |
02:15 ET | 5458 | 17.67 |
02:18 ET | 4730 | 17.6791 |
02:20 ET | 1200 | 17.675 |
02:22 ET | 1095 | 17.695 |
02:24 ET | 1143 | 17.708 |
02:26 ET | 3559 | 17.7 |
02:27 ET | 1562 | 17.72 |
02:29 ET | 1359 | 17.71 |
02:31 ET | 18910 | 17.67 |
02:33 ET | 5662 | 17.65 |
02:36 ET | 1533 | 17.67 |
02:38 ET | 1942 | 17.69 |
02:40 ET | 892 | 17.67 |
02:42 ET | 1106 | 17.7 |
02:44 ET | 1247 | 17.7 |
02:45 ET | 1883 | 17.68 |
02:47 ET | 4117 | 17.69 |
02:49 ET | 300 | 17.695 |
02:51 ET | 1979 | 17.6988 |
02:54 ET | 984 | 17.7 |
02:56 ET | 2094 | 17.68 |
02:58 ET | 10108 | 17.7 |
03:00 ET | 10972 | 17.7 |
03:02 ET | 2200 | 17.695 |
03:03 ET | 6138 | 17.69 |
03:05 ET | 1506 | 17.7 |
03:07 ET | 4497 | 17.74 |
03:09 ET | 2538 | 17.75 |
03:12 ET | 17952 | 17.7567 |
03:14 ET | 3566 | 17.72 |
03:16 ET | 3450 | 17.72 |
03:18 ET | 1010 | 17.715 |
03:20 ET | 3625 | 17.74 |
03:21 ET | 1973 | 17.77 |
03:23 ET | 1302 | 17.785 |
03:25 ET | 4918 | 17.79 |
03:27 ET | 2218 | 17.785 |
03:30 ET | 4421 | 17.81 |
03:32 ET | 5823 | 17.7883 |
03:34 ET | 7331 | 17.83 |
03:36 ET | 1908 | 17.83 |
03:38 ET | 3425 | 17.81 |
03:39 ET | 2263 | 17.815 |
03:41 ET | 10755 | 17.785 |
03:43 ET | 3234 | 17.75 |
03:45 ET | 7553 | 17.745 |
03:48 ET | 8543 | 17.75 |
03:50 ET | 3983 | 17.765 |
03:52 ET | 10822 | 17.77 |
03:54 ET | 9122 | 17.77 |
03:56 ET | 18851 | 17.845 |
03:57 ET | 28795 | 17.86 |
03:59 ET | 327182 | 17.99 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Intellia Therapeutics Inc | 1.8B | -3.3x | --- |
Recursion Pharmaceuticals Inc | 1.7B | -3.7x | --- |
Viridian Therapeutics Inc | 1.8B | -5.6x | --- |
Bicycle Therapeutics PLC | 1.6B | -6.2x | --- |
NewAmsterdam Pharma Company NV | 1.6B | -6.9x | --- |
Soleno Therapeutics Inc | 1.9B | -20.4x | --- |
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8B |
---|---|
Revenue (TTM) | $46.0M |
Shares Outstanding | 101.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.78 |
EPS | $-5.48 |
Book Value | $11.29 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | 39.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,140.05% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.